Patents by Inventor Michael N. Oda
Michael N. Oda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180074079Abstract: The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease.Type: ApplicationFiled: April 14, 2017Publication date: March 15, 2018Applicant: Children's Hospital & Research Center at OaklandInventor: Michael N. ODA
-
Publication number: 20160305967Abstract: The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease.Type: ApplicationFiled: March 23, 2016Publication date: October 20, 2016Inventor: Michael N. ODA
-
Patent number: 9107826Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: GrantFiled: July 10, 2013Date of Patent: August 18, 2015Assignee: Children's Hospital and Research Center at OaklandInventors: Robert O. Ryan, Michael N. Oda
-
Publication number: 20140308339Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: ApplicationFiled: July 10, 2013Publication date: October 16, 2014Inventors: Robert O. RYAN, Michael N. ODA
-
Patent number: 8821939Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: GrantFiled: August 14, 2012Date of Patent: September 2, 2014Assignee: Children's Hospital and Research Center at OaklandInventors: Robert O. Ryan, Michael N. Oda
-
Publication number: 20140162376Abstract: The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease.Type: ApplicationFiled: April 27, 2012Publication date: June 12, 2014Inventor: Michael N. Oda
-
Patent number: 8541236Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.Type: GrantFiled: December 6, 2007Date of Patent: September 24, 2013Assignees: University of Washington, The Children's Hospital & Research Center At OaklandInventors: Jay W. Heinecke, John F. Oram, Michael N. Oda
-
Publication number: 20120309628Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Children's Hospital and Research Center at OaklandInventors: Robert O. Ryan, Michael N. Oda
-
Patent number: 8268357Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: GrantFiled: June 14, 2010Date of Patent: September 18, 2012Assignee: Children's Hospital and Research Center at OaklandInventors: Robert O. Ryan, Michael N. Oda
-
Publication number: 20100311595Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: ApplicationFiled: June 14, 2010Publication date: December 9, 2010Applicant: Children's Hospital and Research Center at OaklandInventors: Robert O. RYAN, Michael N. Oda
-
Patent number: 7824709Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: GrantFiled: February 13, 2004Date of Patent: November 2, 2010Assignee: Children's Hospital and Research Center at OaklandInventors: Robert O. Ryan, Michael N. Oda
-
Publication number: 20080234192Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.Type: ApplicationFiled: December 6, 2007Publication date: September 25, 2008Applicants: WASHINGTON, UNIVERSITY OF, CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLANDInventors: Jay W. Heinecke, John F. Oram, Michael N. Oda
-
Patent number: 7223726Abstract: Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.Type: GrantFiled: January 14, 2003Date of Patent: May 29, 2007Assignee: The Regents of the University of CaliforniaInventors: Michael N. Oda, Trudy M. Forte
-
Publication number: 20040229794Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: ApplicationFiled: February 13, 2004Publication date: November 18, 2004Inventors: Robert O. Ryan, Michael N. Oda
-
Publication number: 20030181372Abstract: Functional Apolipoprotein A-I mutant proteins, having one or more cysteine substitutions and polynucleotides encoding same, can be used to modulate paraoxonase's arylesterase activity. These ApoA-I mutant proteins can be used as therapeutic agents to combat cardiovascular disease, atherosclerosis, acute phase response and other inflammatory related diseases. The invention also includes modifications and optimizations of the ApoA-I nucleotide sequence for purposes of increasing protein expression and optimization.Type: ApplicationFiled: January 14, 2003Publication date: September 25, 2003Applicant: The Regents of the University of CaliforniaInventors: Michael N. Oda, Trudy M. Forte